The present invention provides a method for treating a
disease or condition in a
mammal associated with influx of
extracellular calcium via T type
calcium channels, which comprises administering to the
mammal a therapeutically effective amount of a
T type calcium channel inhibitor, a
prodrug thereof, or a pharmaceutically acceptable salt of said inhibitor or
prodrug, wherein the
T type calcium channel inhibitor has a structure represented by Formula (I): Formula (I), wherein R1 is selected from the group consisting of C1-C4
alkyl, hydroxy and C1-C4 alkoxy; X is selected from the group consisting of N and CH; Z is selected from the group consisting of NH, O, S and CH2; R2 is selected from the group consisting of H, halo, NH2, C1-C4
alkyl, hydroxy and C1-C4 alkoxy; and R3 is selected from the group consisting of H, halo, NH2, C1-C4
alkyl, hydroxy and C1-C4 alkoxy. In one embodiment R1 is selected from the group consisting of C1-C4 alkyl, hydroxyl and C1-C4 alkoxy, X is N, Z is O or CH2, R2 is H, halo, NH2 or hydroxyl and R3 is H.